The Medical University of South Carolina (MUSC) has received a $3.6 million primary award for the Supporting Pediatric Research on Outcomes and Utilization of Telehealth-Clinical and Translational Science Award Collaborative Telehealth Research Network.
The Medical University of South Carolina (MUSC) has received a $3.6 million primary award for the Supporting Pediatric Research on Outcomes and Utilization of Telehealth (SPROUT)-Clinical and Translational Science Award Collaborative Telehealth Research Network. The 5-year grant will focus on supporting the development of telehealth research efforts, metric development, identification of best practices, and the development of collaborative policy and advocacy materialsa cross the country. The grant builds upon current work as part of the SPROUT collaborative, a network of institutions and pediatric providers operating within the American Academy of Pediatrics.
“This is a huge step forward in the development of safe and impactful telehealth programs across the country,” said primary investigator for the grant S. David McSwain, MD, MUSC Children’s Health physician and MUSC associate professor of pediatric critical care and chief medical information officer. “Academic research into the real impact of telehealth services is a critical component of developing and growing programs with the greatest potential to improve our health care system. Many physicians and other health care providers are hesitant about incorporating telehealth into their practices because it’s difficult to separate the theoretical benefits from the real value.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More